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Abstract
Objective—To describe the incidence and outcomes of endophthalmitis after intravitreal 
injections of anti-VEGF agents in the Comparison of Age-related Macular Degeneration 
Treatments Trials (CATT) and to assess the effect of use of prophylactic topical antimicrobials on 
incidence.
Design—Cohort study within a randomized clinical trial.
Participants—Patients enrolled in CATT.
Methods—Patients with neovascular age-related macular degeneration received intravitreal 
injections of ranibizumab or bevacizumab under one of three dosing regimens. The study protocol 
specified pre-injection preparation to include use of a sterile lid speculum and povidone iodine 
(5%). Use of pre-and post-injection antibiotics was at the discretion of the treating 
ophthalmologist. Patients were followed monthly for two years.
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Main Outcome Measures—Development of endophthalmitis and visual acuity.
Results—Endophthalmitis developed after 11 of 18,509 injections (1 per 1,700; 0.06%; 95% 
Confidence Interval (0.03%, 0.11%)), and among 11 of 1185 patients (0.93%; 95% Confidence 
Interval (0.52, 1.66)). Incidence of endophthalmitis was 0.15% among injections with no antibiotic 
use, 0.08% among injections with pre-injection antibiotics only, 0.06% among injections with 
post-injection antibiotics only, and 0.04% among injections with pre-and post-injection antibiotics 
(p=0.20). All eyes were treated with intravitreal antibiotics and 4 had vitrectomy. Among the 11 
affected eyes, the final study visual acuity was 20/40 or better in 4 (36%) eyes, 20/50-20/80 in 2 
(18%) eyes, 20/100-20/160 in 3 (27%) , and <20/800 in 2 (18%) eyes. The final visual acuity was 
within 2 lines of the visual acuity before endophthalmitis in 5 (45%) eyes.
Conclusion—Rates of endophthalmitis were low and similar to those in other large scale 
studies. Use of topical antibiotics either before or after injection does not appear to reduce the risk 
for endophthalmitis.
Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs have 
become one of the most commonly performed procedures in ophthalmology, with an 
estimate of more than 3 million per year for the Medicare population.1 Although infrequent, 
endophthalmitis is the complication of greatest concern due to poor functional outcomes in 
some patients even with prompt treatment.
The rate of endophthalmitis following intravitreal injections varies in the literature. In large 
prospective randomized trials, the endophthalmitis rate ranges from six in an estimated 
26,300 injections (0.02%) to three in 3125 (0.10%).2-4 In retrospective case series, in which 
generally one or a small number of institutions or practices report their findings, the rates 
vary more widely3,4. The largest meta-analysis performed to date analyzed 43 published 
articles and found an endophthalmitis incidence of 197 in 350,535 injections (0.056%) 4
The few generally agreed upon preventive strategies include the use of povidone iodine on 
the ocular surface immediately before the injection and the use of a lid speculum.5 Other 
precautions, such as use of gloves5, and strategies to minimize droplet contamination such 
as use of a mask or minimizing talking during injection remain controversial.6-8
The administration of prophylactic pre- or post-injection topical antibiotics has been 
required in many clinical trials and is routinely practiced by many ophthalmologists. 
Recommendations for antibiotic use have been recently called into question by reports of 
lower endophthalmitis rates among those patients who did not receive pre- or post-injection 
antibiotics in some DRCR.net studies6. Additionally, the use of prophylactic topical 
antibiotics has been demonstrated to cause rapid development of antibiotic resistant virulent 
bacteria on the ocular surface and displacement of commensal flora with more virulent 
species.9-11
We report the rate of endophthalmitis in the Comparison of Age-related Macular 
Degeneration Treatments Trials (CATT), a multicenter randomized clinical trial, and 
describe the impact of endophthalmitis on visual acuity. We also examine the effect of pre- 
or post-injection use on the endophthalmitis rates in this large cohort.
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A detailed discussion of the methodology for the CATT has been published previously12-14. 
From February 2008 through December 2009, 1185 patients from 43 clinical centers in the 
United States were enrolled into the trial. Eyes were eligible for the study if they had active 
choroidal neovascularization secondary to age-related macular degeneration (AMD), no 
previous treatment, and visual acuity between 20/25 and 20/320. Patients were randomized 
to intravitreal injections of either ranibizumab or bevacizumab administered monthly, or pro 
re nata (PRN) for two years, or monthly for one year followed by PRN for one year. 
Bevacizumab was prepared centrally by an aseptic filling facility and distributed in small 
glass vials. Ranibizumab was obtained by each clinic through their normal commercial 
sources. Ophthalmologists were masked to the identity of the drug at the time of treatment 
and throughout follow-up. The study was approved by an institutional review board 
associated with each center. All patients provided written informed consent.
Patients were evaluated every 28 days and treated with intravitreal injections according to 
their assigned treatment. The CATT protocol for intravitreal injection required application 
of 5% povidone iodine and use of a sterile eyelid speculum. Use of topical antibiotic 
medications either before or after the injection was at the discretion of the treating 
ophthalmologist.
Study ophthalmologists examined patients as soon as possible after a report of symptoms of 
endophthalmitis. The diagnosis of presumed endophthalmitis was made by the examining 
ophthalmologist on the basis of clinical examination. Signs of endophthalmitis included the 
presence of pain, decreased visual acuity, conjunctival injection, corneal edema, anterior 
chamber cell and flare, hypopyon, vitritis, and intraretinal hemorrhage. Study 
ophthalmologists initiated treatment with intravitreal antimicrobial medications and, in some 
instances, vitrectomy upon making the diagnosis of presumed endophthalmitis.
All reported cases of presumed endophthalmitis; i.e., treated with intravitreal antibiotics, in 
CATT were identified and reviewed in detail. Cases with positive cultures were classified as 
endophthalmitis. Cases with negative or no cultures and no later episodes of inflammation 
after additional anti-VEGF treatment were also classified as endophthalmitis. However, 
cases with negative cultures that had a subsequent episode of severe inflammation following 
intravitreal injection of the assigned study drug that completely resolved with topical 
steroids only were classified as severe non-infectious inflammation, and not as 
endophthalmitis.
Incidence rates and associated 95% confidence intervals were calculated on a per injection 
basis and a per patient basis.15 Comparisons of rates were evaluated by chi-square tests with 
exact calculations of p-values.
Results
Eleven eyes developed endophthalmitis after 18,509 injections in 1185 patients (Table 1). 
The incidence rate per injection was 0.06% (95% Confidence Interval (0.03%, 0.11%) or 1 
per 1,700 injections. The incidence rate per patient was 0.93% (95% Confidence Interval 
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(0.52%, 1.66%)). Of the eleven eyes with endophthalmitis, four were treated with 
ranibizumab and seven with bevacizumab.
Incidence rates of endophthalmitis for four groups defined by use of topical antibiotics 
before and after injection are displayed in Table 1. Antibiotics were used both before and 
after injection for 9961 (54%) injections and were not used at either time for 2000 (11%) 
injections. The rate of endophthalmitis was highest in the group with no antibiotic use 
(0.15%) and lowest in the group with antibiotics administered both before and after (0.04%); 
however, the differences in incidence rates among the four groups were not statistically 
significant (p=0.20). Povidone iodine was used per protocol for 18,332 (99.04%) of the 
18,509 injections. Among the 11 injections resulting in endophthalmitis, povidone iodine 
was used for 10 and not used for one (Table 2, Week 56) because the patient had an allergy 
to shellfish.
Of the 11 endophthalmitis patients, one patient had no culture, one had a specimen obtained 
at primary vitrectomy, two had anterior chamber tap alone and seven had vitreous tap. Of 
the ten cultures, three were negative, three were positive for staphylococcus epidermidis, 
one was positive for staphylococcus aureus, and three were positive for streptococcal species 
(Table 2). Three patients had a vitrectomy between 5 days and 2 months after the initial 
treatment for endophthalmitis.
Among 11 affected eyes, the final study visual acuity was 20/40 or better in 4 (36%) eyes, 
20/50-20/80 in 2 (18%) eyes, 20/100-20/160 in 3 (27%) , and <20/800 in 2 (18%) eyes 
(Table 2). The final visual acuity was within 2 lines of the visual acuity before 
endophthalmitis in 5 (45%) of eyes.
In addition to the 11 eyes that developed endophthalmitis, three (0.25%; 95% Confidence 
Interval (0.08%, 0.74%)) of the 1185 eyes developed severe non-infectious inflammation. 
For two of the patients, the post-injection inflammation initially was presumed to be due to 
endophthalmitis and treated with intravitreal antibiotics. Vitreous samples were negative for 
bacteria or fungus. Each patient subsequently developed severe inflammation similar to the 
original episode immediately after the next challenge with the same drug (ranibizumab in 
one case and bevacizumab in one case) and in each case, the inflammation resolved with 
topical steroids only and no antibiotics. One additional patient, treated with ranibizumab, 
developed severe post-injection inflammation considered by the treating ophthalmologist to 
be an immune phenomenon, and the episode resolved promptly with topical steroid therapy.
Discussion
The rates of endophthalmitis in CATT (0.06% per injection, 0.93% per patient) are 
consistent with the results of other large clinical trials of intraocular injections of anti-VEGF 
agents.16-21. The ratio of culture negative to culture positive cases was similar to post-
operative endophthalmitis after cataract surgery, and visual acuity outcomes after treatment 
were consistent with large series of post cataract surgery endophthalmitis.22-24
The rate of infection did not appear to be influenced by the use of topical antibiotic 
medication before or after the injection. While most practitioners agree on the use of topical 
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povidone iodine and a lid speculum for intravitreal injections, the use of antibiotics in 
conjunction with intravitreal injections has changed substantially over the last 10 years. 
Since anti-VEGF injection became common clinical practice in 2005, pre- or post- injection 
topical antibiotics have been used in the vast majority of cases. In CATT, investigators 
elected to use pre- or post- injection antibiotics in 90% of the intravitreal injections given 
during the period of study between February 2008 and December 2011. The practice was 
supported by clinical conjunctival culture data demonstrating significant reduction in 
positive conjunctival cultures following antibiotic instillation. 25, 26
More recently, several studies demonstrating increased antibiotic resistance in conjunctival 
bacteria due to repeated topical antibiotic exposure and an apparent lack of efficacy in 
preventing endophthalmitis, have resulted in a dramatic decline of topical antibiotic 
use. 9-11,27,28 Bhavsar and colleagues reported the rate of endophthalmitis in four DRCRnet 
studies among patients using and not using topical prophylactic antibiotics.6,29 The 
endophthalmitis rate was higher among those using prophylactic topical antibiotics than 
those not using antibiotics (0.13% versus 0.03%; p=0.25). Similarly, Bhatt and colleagues 
found no difference in endophthalmitis rates between 2,287 patients who received topical 
antibiotics and 2,480 patients who did not.16 Cheung and colleagues found the lowest rate of 
endophthalmitis among more than 15,000 injections in eyes that did not receive any 
prophylactic antibiotics.30
Following the reports of emerging resistance and limited effectiveness, there has been a 
dramatic shift away from using topical antibiotics in the peri-injection setting. In annual 
surveys by the American Society of Retina Specialists, the proportion of members reporting 
use of topical antibiotics decreased from approximately 90% in 2008 to 20% in 2013.31,32 
The totality of the published evidence at this point, combined with the findings in CATT, do 
not support a clinically important benefit of prophylactic topical antibiotics in reducing the 
risk of endophthalmitis following intravitreal injections.
Among the CATT culture positive endophthalmitis cases, three of seven (42%) were a 
Streptococcus species. Higher rates of Streptococcus species following intravitreal injections 
than after intraocular surgery have been previously reported.33,34 McCannel and Wen have 
suggested that oropharyngeal droplet contamination may be responsible.35 Although still 
controversial, recommendations for reducing risk of Streptococcal endophthalmitis include 
controlling droplet contamination with such measures as minimizing speaking during the 
injection, or wearing a facemask.
There were three cases of severe non-infectious inflammation after injection in CATT that 
were of particular interest. In each case, there was convincing evidence that the 
inflammation was not due to infection. All cultures were negative, but negative cultures 
have been reported in several studies of endophthalmitis when it was highly likely that an 
infectious organism was present.21,36 Instead, what was unique in these three cases was that 
the inflammation either completely resolved with topical steroids alone and no antibiotic 
(one case following a ranibizumab injection), or the patient developed a recurrent episode of 
severe inflammation similar to the original event with subsequent injection of the same anti-
VEGF injection (one case with ranibizumab and one with bevacizumab), and the 
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inflammation resolved with topical steroids and no antibiotics. These cases highlight the fact 
that not all cases of severe inflammation after injection are infectious and that there is a 
clinical distinction between severe non-infectious inflammation and infectious 
endophthalmitis. Severe non-infectious inflammation is used to denote a transient, self-
limited inflammatory reaction that occurs after intravitreal injection. This is distinguished 
from infectious endophthalmitis where the source of inflammation is an intraocular 
microbe.4
Eyes with severe non-infectious inflammation, also referred to in the literature as non-
infectious endophthalmitis, have a typical clinical presentation. Patients usually have 
symptoms of decreased vision and minimal pain soon after the intravitreal injection (i.e. day 
0-day 2). Patients develop marked anterior chamber reaction with cell and flare but often 
will not have hypopyon or fibrin. Posteriorly, patients develop a “pseudogranulomatous” 
appearance, with large cellular aggregates and moderate vitreous haze.37 This contrasts with 
the presentation of infectious endophthalmitis, where findings of pain, decreased visual 
acuity, conjunctival injection, corneal edema, anterior chamber cell and flare, hypopyon, 
fibrin, vitritis, and intraretinal hemorrhage typically occur two or more days after injection, 
when the micro-inoculum of bacteria has had time to cause a consequential cellular reaction.
In summary, the rate (0.06%, or 1 per 1,700) of endophthalmitis in CATT per injection was 
similar to rates in other large clinical trials evaluating anti-VEGF drugs for neovascular 
AMD. Topical antibiotics used before or after injection did not result in a statistically or 
clinically significant reduction in the risk for endophthalmitis (p=0.20). Patients who 
developed endophthalmitis were treated with intravitreal antibiotics and in 4 cases (36%), 
vitrectomy. The final study visual acuity was within 2 lines of the visual acuity before 
endophthalmitis in 5 (45%) of 11 eyes. Three patients developed severe non-infectious 
inflammation that resolved with topical steroids.
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Table 1
Incidence of Endophthalmitis by Use of Antibiotics
Antibiotic Use Injections Cases Rate 95% Confidence Interval
None 2000 3 0.15% (0.05%, 0.44%)
Pre-injection only 1301 1 0.08% (0.01%, 0.43%)
Post-injection only 5247 3 0.06% (0.05%, 0.25%)
Pre- and post-injection 9961 4 0.04% (0.02%, 0.10%)
Total 18509 11 0.06% (0.03%, 0.11%)
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